The European Commission (EC) has approved a respiratory syncytial virus (RSV) vaccine for the treatment of adult patients with lower respiratory tract disease (LRTD) caused by RSV.  Arexy, an adjuvanted recombinant RSV vaccine developed by GSK, will now be available to adult patients in European countries. The treatment was previously approved in adults aged 60 years […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!